直接口服抗凝药用于瓣膜修复或生物瓣置换术后早期心房颤动
回顾性注册队列研究纳入1743例瓣膜修复或生物瓣置换术后合并心房颤动的出院口服抗凝患者,比较直接口服抗凝药(DOAC)与华法林术后3个月内的有效性和安全性。DOAC组复合有效结局17例(2%)、复合安全结局55例(10%),华法林组分别为41例(3%)和114例(10%),校正后比较均无统计学显著差异,30天再入院率相似。作者认为DOAC可能是华法林的替代选择,但需足够效能的前瞻性研究确认。
要点
- 术后早期DOAC组复合有效结局17例(2%),华法林组41例(3%)。
- 复合安全结局DOAC组55例(10%),华法林组114例(10%)。
- 校正后有效性和安全性比较均无统计学显著差异,30天再入院率相似。
核心结论
- 作者认为DOAC可能是瓣膜修复或外科生物瓣置换术后早期华法林的替代选择,但需足够效能的前瞻性研究确认。
研究设计与样本
- 回顾性、注册-informed队列研究,纳入瓣膜修复或生物瓣置换术后合并心房颤动且出院时接受口服抗凝的手术患者1743例。
主要发现
- DOAC组570例中17例(2%)达到复合有效结局,华法林组1173例中41例(3%)达到复合有效结局。
- DOAC组570例中55例(10%)达到复合安全结局,华法林组1173例中114例(10%)达到复合安全结局。
- 复合有效结局的校正比值比为0.85(95%CI 0.46-1.55,P=0.59),复合安全结局的校正比值比为0.94(95%CI 0.66-1.34,P=0.76),均无统计学显著差异。
- 两组30天再入院率相似。
关键数值与推荐
- 主要有效结局为死亡、缺血性卒中、短暂性脑缺血发作和系统性栓塞的复合终点。
- 主要安全结局为大出血的复合终点。
临床怎么用
- 作者认为DOAC可能是瓣膜修复或外科生物瓣置换术后早期华法林的替代选择,但需足够效能的前瞻性研究确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite increased use of direct oral anticoagulants (DOACs), limited evidence guides their use in the early postoperative period after bioprosthetic valve implantation in patients with atrial fibrillation. Our objective was to describe the efficacy and safety of DOACs and warfarin in the first 3 months after surgical bioprosthetic valve replacement or repair in patients with atrial fibrillation. METHODS: This was a retrospective, registry-informed cohort study of surgical patients who underwent bioprosthetic valve replacement or repair, had concomitant atrial fibrillation and received oral anticoagulation at discharge. The primary efficacy outcome was a composite of death, ischemic stroke, transient ischemic attack, and systemic embolism; the primary safety outcome was a composite of major bleeding. Key secondary outcomes were comparative analyses of primary outcomes, temporal anticoagulation prescribing patterns, and 30-day readmission rates. RESULTS: A total of 1743 patients were included. Of the 570 patients in the DOAC group, 17 (2%) met the composite efficacy outcome and 55 (10%) met the composite safety outcome. Of the 1173 patients receiving warfarin, 41 (3%) and 114 (10%) met the composite efficacy and safety outcomes, respectively. Comparative secondary analysis was not statistically significant for either the efficacy (adjusted odds ratio, 0.85; 95% confidence interval, 0.46-1.55, P = .59) or safety (adjusted odds ratio, 0.94; 95% confidence interval, 0.66-1.34, P = .76) outcomes. The 30-day readmission rates were similar between both groups. CONCLUSIONS: Our results suggest DOACs may be safe and effective alternatives to warfarin in the early postoperative period after valve repair or surgical bioprosthetic replacement. Confirmation awaits adequately powered prospective studies.
引用
- Moser N, Omar MA, Koshman SL, et al. Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement. J Thorac Cardiovasc Surg. 2023. PMID: 37061910. doi:10.1016/j.jtcvs.2023.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。